A Double-Blind, Active-Controlled, Long-Term Safety Extension Study of Optimized Doses of Darusentan in Subjects With Resistant Hypertension Despite Receiving Combination Therapy With Three or More Antihypertensive Drugs, Including a Diuretic, as Compared to Guanfacine (Protocol DAR-312-E) [EXTENSION OF 700013256]

Trial Profile

A Double-Blind, Active-Controlled, Long-Term Safety Extension Study of Optimized Doses of Darusentan in Subjects With Resistant Hypertension Despite Receiving Combination Therapy With Three or More Antihypertensive Drugs, Including a Diuretic, as Compared to Guanfacine (Protocol DAR-312-E) [EXTENSION OF 700013256]

Discontinued
Phase of Trial: Phase III

Latest Information Update: 01 Apr 2014

At a glance

  • Drugs Darusentan (Primary) ; Guanfacine
  • Indications Resistant hypertension
  • Focus Therapeutic Use
  • Acronyms DORADO-AC-EX
  • Sponsors Gilead Sciences; Myogen
  • Most Recent Events

    • 01 Apr 2014 New source identified and integrated (EudraCT2006-003548-42).
    • 28 Mar 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top